VBI is developing a prophylactic vaccine to prevent cytomegalovirus (“CMV”) infection. CMV is a leading cause of prenatal developmental delays. VBI has completed work for GMP manufacturing of its lead candidate for use in Phase I trials. VBI expects to evaluate safety, tolerability, and also immunological proof of concept in humans during Phase I trials by measuring CMV neutralizing antibodies in fibroblasts and epithelial cells.